235 related articles for article (PubMed ID: 9050327)
1. Refractory IBD: medical management.
Tremaine WJ
Neth J Med; 1997 Feb; 50(2):S12-4. PubMed ID: 9050327
[TBL] [Abstract][Full Text] [Related]
2. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases.
Meuwissen SG; Ewe K; Gassull MA; Geboes K; Jewell D; Pallone F; Rachmilewitz D; Rask-Madsen J; Riddell BH; Sandborn BJ; Schmuck ML
Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):13-8. PubMed ID: 10656204
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive drugs in the treatment of inflammatory bowel disease.
Aranda R; Horgan K
Semin Gastrointest Dis; 1998 Jan; 9(1):2-9. PubMed ID: 9547850
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine.
Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL
Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease.
Lamers CB; Griffioen G; van Hogezand RA; Veenendaal RA
Scand J Gastroenterol Suppl; 1999; 230():111-5. PubMed ID: 10499471
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine: state of the art in inflammatory bowel disease.
Sandborn WJ
Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
9. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD].
Reinisch W; Dejaco C; Knoflach P; Petritsch W; Vogelsang H; Tilg H
Z Gastroenterol; 2004 Sep; 42(9):1033-45; discussion 1046-7. PubMed ID: 15455280
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
[TBL] [Abstract][Full Text] [Related]
12. [The use of methotrexate in an inflammatory bowel diseases based on the review of the current literature].
Klimczak K; Łykowska-Szuber L; Krela-Kaźmierczak I; Eder P; Szymczak A; Stawczyk-Eder K; Linke K
Wiad Lek; 2016; 69(2 Pt 2):262-6. PubMed ID: 27487545
[TBL] [Abstract][Full Text] [Related]
13. [Cyclosporine in inflammatory bowel disease].
Colomina Avilés J; Pascual Pérez R; Ortuño Cortés J; García García A; Del Pino Cuadrado J
An Med Interna; 1998 Apr; 15(4):214-8. PubMed ID: 9608068
[TBL] [Abstract][Full Text] [Related]
14. Review article: monitoring of immunomodulators in inflammatory bowel disease.
Aberra FN; Lichtenstein GR
Aliment Pharmacol Ther; 2005 Feb; 21(4):307-19. PubMed ID: 15709982
[TBL] [Abstract][Full Text] [Related]
15. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
17. General principles of medical therapy of inflammatory bowel disease.
Friedman S
Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
[TBL] [Abstract][Full Text] [Related]
18. Medical management of patients with difficult-to-treat inflammatory bowel disease.
van Hogezand RA
Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive treatment for refractory ulcerative colitis--where do we stand and where are we going?
Schölmerich J
Eur J Gastroenterol Hepatol; 1997 Sep; 9(9):842-9. PubMed ID: 9355780
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
